Ascendis Pharma A/S
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jan Moller Mikkelsen
- Full Time Employees
- 1,189
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Tuborg Boulevard 12 Hellerup CR Denmark 2900
- IPO Date
- Jan 28, 2015
- CIK
- 0001612042
- Website
- ascendispharma.com
- Similar Companies
- Business
- Ascendis Pharma A/S, a biopharmaceutical company headquartered in Hellerup, Denmark, and founded in 2007, develops and commercializes TransCon-based therapies addressing unmet needs in endocrinology rare diseases and oncology. The company applies its proprietary TransCon technology platform, which enables sustained release of parent drugs to optimize therapeutic profiles, to create product candidates focused on patient safety, efficacy, tolerability, and convenience. Core approved products include SKYTROFA (lonapegsomatropin-tcgd), a once-weekly treatment for pediatric growth hormone deficiency authorized in the United States and the European Union/EEA and commercially available in the United States; and YORVIPATH (palopegteriparatide), a therapy for adults with hypoparathyroidism authorized in the United States, European Union, EEA, and United Kingdom. The pipeline features investigational candidates such as TransCon CNP (navepegritide), a long-acting prodrug in late-stage development for achondroplasia in children with a U.S. PDUFA target date of February 28, 2026 following FDA priority review and extension; as well as other endocrinology rare disease and oncology programs. Operations span North America, Europe, and rest-of-world markets with research facilities in Germany and offices across Europe and the United States; in 2018, Ascendis formed VISEN Pharmaceuticals, granting it exclusive rights to its endocrinology portfolio including TransCon hGH, TransCon PTH, and TransCon CNP in Greater China, with recent supply framework agreements extending through 2027. Recent developments encompass a September 2024 $150 million capped synthetic royalty financing agreement with Royalty Pharma on U.S. net sales of YORVIPATH to support U.S. launch and global capabilities; a February 2025 authorization of a $25 million share repurchase program; strong third-quarter 2025 financial performance with €143.1 million in YORVIPATH revenue and €50.7 million in SKYTROFA revenue alongside operating profit of €11.0 million; and ongoing pipeline advancements including TransCon CNP regulatory progress.
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
Ascendis Pharma A/S Q2 Earnings Call Highlights
Ascendis Pharma Reports Second Quarter 2026 Financial Results
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
Why Crinetics Stock Soared 99% This Week
14 value stocks of companies primed for rapid growth through 2028
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma Reports First Quarter 2026 Financial Results
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028